Recombinant Human B7-H4 Mouse IgG2a Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10641-B7

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10641-B7-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

NP_078902

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all B7-H4 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human B7-H4 protein
Human B7-H4
(Phe29-Ala258)
Accession # NP_078902		 IEGRMDP Mouse IgG2a
(Glu98-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Phe29

Predicted Molecular Mass

52 kDa

SDS-PAGE

75-85 kDa, under reducing conditions

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells.
The ED50 for this effect is 0.2-4 μg/mL.

Scientific Data Images for Recombinant Human B7-H4 Mouse IgG2a Fc Chimera Protein, CF

Recombinant Human B7-H4 Mouse IgG2a Fc Chimera Protein Bioactivity.

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion by human T cells. The ED50 for this effect is 0.2-4 μg/mL.

Recombinant Human B7-H4 Mouse IgG2a Fc Chimera Protein SDS-PAGE

2 μg/lane of Recombinant Human B7-H4 Mouse IgG2a Fc Chimera (Catalog # 10641-B7) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-85 kDa and 150-170 kDa, respectively.

Formulation, Preparation and Storage

10641-B7
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: B7-H4

B7-H4, also known as B7x and B7S1, is a 50-80 kDa glycosylated member of the B7 family of immunomodulatory proteins (1, 2). Mature human B7-H4 consists of a 235 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a 21 aa transmembrane segment, and a 2 aa cytoplasmic tail (3-5). Within the ECD, human B7-H4 shares 90% aa sequence identity with mouse and rat B7-H4. It shares 22% - 28% aa sequence identity with human B7-1, B7-2, B7-H1, B7-H2, B7-H3, and PD-L2. Alternate splicing of human B7-H4 generates an additional isoform that lacks the first Ig-like domain. B7-H4 is expressed on the surface of activated lymphocytes, macrophages, monocytes, dendritic cells, epithelial cells, and bone marrow-derived mesenchymal stem cells (4-8). Its binding to activated T cells dampens T cell responses and induces cell cycle arrest in the T cell (3-5). Reverse signaling can induce either cell cycle arrest or apoptosis in the B7-H4 expressing cell (9, 10). B7-H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13-15). Soluble B7-H4 functions as a decoy molecule that blocks the inhibitory influence of B7-H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).

References

  1. Yi, K.H. and L. Chen (2009) Immunol. Rev. 229:145.
  2. Salceda, S. et al. (2005) Exp. Cell Res. 306:128.
  3. Zang, X. et al. (2003) Proc. Natl. Acad. Sci. 100:10388.
  4. Prasad, V.R. et al. (2003) Immunity 18:863.
  5. Sica, G.L. et al. (2003) Immunity 18:849.
  6. Kryczek, I. et al. (2006) J. Exp. Med. 203:871.
  7. Tringler, B. et al. (2005) Clin. Cancer Res. 11:1842.
  8. Xue, Q. et al. (2010) Stem Cells Dev. 19:27.
  9. Song, H. et al. (2008) Cancer Lett. 266:227.
  10. Park, G.B. et al. (2009) Immunology 128:360.
  11. Zang, X. et al. (2007) Proc. Natl. Acad. Sci. 104:19458.
  12. Krambeck, A.E. et al. (2006) Proc. Natl. Acad. Sci. 103:10391.
  13. Simon, I. et al. (2006) Cancer Res. 66:1570.
  14. Thompson, R.H. et al. (2008) Cancer Res. 68:6054.
  15. Azuma, T. et al. (2009) PloS Med. 6:e1000166.
  16. Suh, W.-K., et al. (2006) Mol. Cell. Biol. 26:6403.

Long Name

B7 Homolog 4

Alternate Names

B7H4, B7S1, B7x, Vtcn1

Entrez Gene IDs

79679 (Human); 242122 (Mouse); 295322 (Rat)

Gene Symbol

VTCN1

UniProt

NP_078902

Additional B7-H4 Products

Product Documents for Recombinant Human B7-H4 Mouse IgG2a Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human B7-H4 Mouse IgG2a Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.